Proactive and included patients can help clinical trial retention.
Examining the views of different stakeholders in the ecosystem supporting drug R&D.
Three areas where the pharma industry will advance in 2017 as it looks beyond the hype.
How do we get to the point where patient centricity is at the core of clinical trials?
More needs to be done to ensure patient centricity is at the heart of all clinical trials.
How should the industry define patient-centricity, and how should progress be measured?
CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.